-
Study aim
-
The aim of this study was to evaluate the effectiveness of Neurofeedback on psychological stress and salivary cortisol and α-amylase level in students
-
Design
-
This study is a randomized, double -blind, with parallel groups clinical trial. Sixty students with Anxiety symptoms in two groups of 30 people in a trial are assigned randomly.
-
Settings and conduct
-
Location is Fetros Comprehensive Health Center. Sixty participants are selected. Thirty participants in control group and 30 participants in neurofeedback are assigned randomly. In this double-blind study, the psychiatrist and data analyser are kept blind to the treatment. Participants pick up envelopes inside the box randomly which are in an unspecified wrapper.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Achieving a score above 18 on the stress scale of the Stress, Anxiety and Depression Questionnaire (DASS-21), and age range between 18 to 25 years old, Exclusion criteria: Presence or history of severe psychiatric disorders (including periods of severe depression, anxiety disorders, substance use disorders), Smoking and psychedelic pills use, using psychiatric drugs,
epilepsy, various cardiovascular and respiratory disorders and blood pressure
-
Intervention groups
-
The intervention group is the neurofeedback group and the control group is the non-experimental group. Participants in the intervention group receive 2 sessions of 30 minutes of neurofeedback training every week. The control group received no intervention.
-
Main outcome variables
-
Anxiety symptoms, stress, cortisol, α amylase